Business Context and Reporting Period
This Form 8-K is filed by Processa Pharmaceuticals, Inc. (PCSA) on August 7, 2025. The filing addresses a regulatory matter regarding the continued listing of the Company's common stock on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on listing compliance status rather than financial performance metrics.
Material Changes and Listing Status
- Previous Notice: The Company previously received notice on February 4, 2025, that its stock bid price had closed below the $1.00 minimum requirement for 30 consecutive business days.
- Current Status: On August 7, 2025, Nasdaq granted the Company a second 180-day grace period to regain compliance, extending until February 2, 2026.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days during this period.
- Eligibility Basis: The extension was granted because the Company meets all other Nasdaq initial listing standards, including the market value of publicly held shares.
Outlook, Management Commentary, and Risks
- Remediation Plan: Management intends to cure the deficiency by effecting a reverse stock split if necessary.
- Trading Status: The stock will continue to be listed and traded on the Nasdaq Capital Market during the grace period, subject to compliance with other listing requirements.
- Risk: Failure to meet the $1.00 bid price requirement by February 2, 2026, could result in delisting.
Investor Verification Checklist
- Verify the current market price of PCSA stock relative to the $1.00 threshold.
- Monitor for a shareholder vote or announcement regarding a proposed reverse stock split.
- Confirm the Company's market value of publicly held shares to ensure continued eligibility for the grace period.
- Review future 8-K filings for updates on compliance status before the February 2, 2026 deadline.